Skip to main content

Table 1 Patient characteristics

From: Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial

  

Azithromycin (n = 42)

Placebo (n = 42)

Age (years), mean (SD)

 

67 (9)

68 (10)

Male sex, n (%)

 

31 (74)

32 (76)

FEV1 (L), mean (SD)

 

1.41 (0.52)

1.32 (0.42)

FEV1 %predicted, mean (SD)

 

49.8 (16.4)

47.4 (12.9)

FEV1/FVC ratio (%),mean (SD)

 

42.2 (11.9)

43.2 (11.7)

BMI (kg/m2), mean (SD)

 

27.2 (4.3)

25.7 (5.8)

Pack years, median (range)

 

30.5 (3-110)

30.0 (1-69)

Current smoker, n (%)

 

14 (33)

15 (36)

Blood values,

CRP (mg/L), median (range)

6.5 (0-46)

4.0 (0-25)

 

ASAT (U/L)* mean (SD)

24.2 (6.5)

26.4 (9.8)

 

ALAT (U/L)* mean (SD)

24.4 (8.0)

24.4 (13.7)

LCQ scores, mean (SD)

Total

14.5 (2.3)

13.4 (3.3)

 

Physical

4.3 (0.7)

4.2 (1.0)

 

Psychological

5.1 (1.0)

4.7 (1.1)

 

Social

5.0 (1.1)

4.5 (1.5)

Bronchiectasis, n (%)

 

18 (42.9)

16 (38.1)

Inhaled medication, n (%)

Long acting beta2 agonists

34 (81.0)

35 (83.3)

 

Long acting anticholinergics

27 (64.3)

24 (57.1)

 

Corticosteroids

41 (98.0)

35 (83.0)

Number of exacerbations in previous year, median (range)

 

1 (0-8)

1 (0-13)

  1. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; BMI, body mass index; CRP, C-reactive protein; ASAT, aspartate transaminase; ALAT, alanine aminotransferase; LCQ, Leicester Cough Questionnaire. Total scores range from 3-21 and domain scores from 1-7. Higher scores signify better health status.
  2. * In ASAT and ALAT n = 41.